PD-L1 blockade for urothelial carcinoma

OncoImmunology

Volumn 6, Issue 7, 2017, Pages

  Kang, Josephine ^a   Galluzzi, Lorenzo ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; ATEZOLIZUMAB; AVELUMAB; CHECKPOINT KINASE INHIBITOR; DURVALUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TOLL LIKE RECEPTOR;

ARTHRALGIA; BLADDER CARCINOMA; CONSTIPATION; EDITORIAL; FATIGUE; HUMAN; MYCOBACTERIUM BOVIS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

EID: 85021435566     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1334028     Document Type: Editorial

References (16)

1. Buque A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, et al. Trial watch:Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015; 4:e1008814; PMID:26137403; https://doi.org/10.1080/2162402X.2015.1008814
2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67:7-30; PMID:28055103; https://doi.org/10.3322/caac.21387
3. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415-21; PMID:23945592; https://doi.org/10.1038/nature12477
4. Iribarren K, Bloy N, Buque A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, et al. Trial watch:Immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology 2016; 5:e1088631; PMID:27141345; https://doi.org/10.1080/2162402X.2015.1088631
5. Board PATE. PDQ Bladder Cancer Treatment. Bethesda, MD:National Cancer Institute.
6. Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ, Kaufman DS. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006; 24:3451-7; PMID:16849761; https://doi.org/10.1200/JCO.2005.03.6699
7. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20:937-40; PMID:11844814; https://doi.org/10.1200/JCO.2002.20.4.937
8. Bambury RM, Benjamin DJ, Chaim JL, Zabor EC, Sullivan J, Garcia-Grossman IR, Regazzi AM, Ostrovnaya I, Apollo A, Xiao H, et al. The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma:A large single-institution experience. Oncologist 2015; 20:508-15; PMID:25845990; https://doi.org/10.1634/theoncologist.2014-0354
9. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy:A single-arm, multicentre, phase 2 trial. Lancet 2016; 387:1909-20; PMID:26952546; https://doi.org/10.1016/S0140-6736(16)00561-4
10. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275):A multicentre, single-arm, phase 2 trial. Lancet Oncol 2017; 18:312-22; PMID:28131785; https://doi.org/10.1016/S1470-2045(17)30065-7
11. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376:1015-26; PMID:28212060; https://doi.org/10.1056/NEJMoa1613683
12. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016; 34:3119-25; PMID:27269937; https://doi.org/10.1200/JCO.2016.67.9761
13. Powles T, O'Donnell PH, Massard C, Arkenau H, Friedlander TW, Hoimes C, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, et al. Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma. Journal of Clinical Oncology 35, no. 6_suppl (February 2017) 286-286; https://doi.org/10.1200/JCO.2017.35.6_suppl.286
14. Heery CR, O'Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marte JL, Lepone LM, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor):A phase 1a, multicohort, dose-escalation trial. Lancet Oncol 2017; 18:587-98; PMID:28373007; https://doi.org/10.1016/S1470-2045(17)30239-5
15. Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032):A multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 2016; 17:1590-8; PMID:27733243; https://doi.org/10.1016/S1470-2045(16)30496-X
16. Paluch BE, Glenn ST, Conroy JM, Papanicolau-Sengos A, Bshara W, Omilian AR, Brese E, Nesline M, Burgher B, Andreas J, et al. Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. Oncotarget 2017; 8:3197-205. PMID:27911273; https://doi.org/10.18632/oncotarget.13691